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Ligand-binding of Cys-loop receptors is determined by N-terminal extracellular loop
structures from the plus as well as from the minus side of two adjacent subunits in the
pentameric receptor complex. An aromatic residue in loop B of the glycine receptor (GlyR)
undergoes direct interaction with the incoming ligand via a cation-pi interaction. Recently,
we showed that mutated residues in loop B identified from human patients suffering from
hyperekplexia disturb ligand-binding. Here, we exchanged the affected human residues
by amino acids found in relatedmembers of the Cys-loop receptor family to determine the
effects of side chain volume for ion channel properties. GlyR variants were characterized
in vitro following transfection into cell lines in order to analyze protein expression,
trafficking, degradation and ion channel function. GlyR α1 G160 mutations significantly
decrease glycine potency arguing for a positional effect on neighboring aromatic residues
and consequently glycine-binding within the ligand-binding pocket. Disturbed glycinergic
inhibition due to T162 α1 mutations is an additive effect of affected biogenesis and
structural changes within the ligand-binding site. Protein trafficking from the ER toward
the ER-Golgi intermediate compartment, the secretory Golgi pathways and finally the cell
surface is largely diminished, but still sufficient to deliver ion channels that are functional
at least at high glycine concentrations. The majority of T162 mutant protein accumulates
in the ER and is delivered to ER-associated proteasomal degradation. Hence, G160 is an
important determinant during glycine binding. In contrast, T162 affects primarily receptor
biogenesis whereas exchanges in functionality are secondary effects thereof.
Keywords: Cys-loop receptor, glycine receptor, loop B, side chain properties, ligand potencies, hyperekplexia
Abbreviations: GlyR, glycine receptor; wt, wild type; ECD, extracellular domain; TM, transmembrane; ER, Endoplasmic
reticulum; Cys, cysteine.
Atak et al. Loop B Residues and Glycine Potency
INTRODUCTION
Glycine receptors (GlyRs) are heteropentameric ligand-gated
ion channels and belong into the superfamily of Cys-loop
receptors (Lynch, 2004). Glycinergic disinhibition based on GlyR
mutations is associated with neuromotor deficiencies (Schaefer
et al., 2013). The immunoglobulin-like structure of the GlyR
N-terminus is determined by a short α-helix and 10 β-sheets
connected by loop structures forming the large extracellular
domain (ECD) followed by four transmembrane domains (TM1-
4) and a short C-terminus (Du et al., 2015; Huang et al., 2015;
Moraga-Cid et al., 2015). The ECD harbors the agonist and
antagonist binding sites formed by loops A, B, C from one
subunit and loops E, F, G from an adjacent subunit (Brams et al.,
2011; Yu et al., 2014). The inhibitory GlyR complex is formed by
three α subunits (α1, α2, α3) and a single β subunit arranged in a
2α:3β configuration (Grudzinska et al., 2005).
Glycinergic inhibition is most important in adult brain
stem and spinal cord mediating processes such as motor
control, pain sensitization and respiratory rhythm. Concerning
the nerve-muscle circuit, GlyRs are postsynaptically expressed
in the membrane of motoneurons. Upon glycine-release
from neighboring inhibitory interneurons GlyRs get activated
and a chloride ion influx leads to hyperpolarization of the
motoneurons, balancing excitation, and consequently muscle
contraction and relaxation (Rajendra et al., 1997).
Mutations in the GlyR α1 subunit gene GLRA1 are
the most common cause for the rare neuromotor disorder
hyperekplexia (Stiff baby syndrome, Startle disease, OMIM
149100). Typical symptoms are neonatal hypertonia and
exaggerated startle response observed shortly after birth. Several
mutations associated with hyperekplexia have been detected
all over the GlyR α1 sequence. Most dominant mutants
cluster in TM2 forming the ion channel domain and adjacent
loop structures with some exceptions. Recessive mutations are
distributed over the entire α1 sequence (Harvey et al., 2008;
Schaefer et al., 2013; Bode and Lynch, 2014). A previous
classification of dominant mutants affecting channel function
and recessive mutants disrupting receptor biogenesis has
recently been specified by defective neuronal subcompartimental
trafficking. This study concentrated on GlyR loop B (G160R,
T162M) and loop D (W68C, D70N, R72H) residues (Schaefer
et al., 2015). Translational approaches based on human
mutations from patients identified important GlyR residues
associated with ligand-binding, conformational changes, ion
channel gating, opening, desensitization, and trafficking (Saul
et al., 1999; Villmann et al., 2009; Chung et al., 2010; Bode and
Lynch, 2013; Bode et al., 2013). The process of ligand-binding is
not only mediated by residues within the binding site, but also
by the small extracellular loop between TM2-3. The underlying
mechanism is thought to involve conformational rearrangements
further down in the structure (Maksay et al., 2008; Pless and
Lynch, 2009; Lape et al., 2012). Other residues such as P250
localized in loop TM1-2 increase receptor desensitization by
altering TM positioning after ion channel opening (Saul et al.,
1999; Breitinger et al., 2001). Furthermore, affected arginine
residues at the N-terminal end of transmembrane helices
(R252 before TM2 and R392 lining TM4) are important start
or stop signals for TM helices and therefore most probably
interfere with receptor membrane integration. Other residues
in recessive hyperekplexia (S231 and I244) localized in TM1
have only marginal effects on receptor biogenesis. The observed
decrease in amount of receptor at the cell surface is still
sufficient to form functional channels (Vergouwe et al., 1999;
Villmann et al., 2009). A recent study on mutations in loop
D, which is opposed to the protein surface, showed a largely
diminished receptor trafficking due to accumulation of the
majority of mutated receptor protein in the ER compartment.
Based on a cellular lack of quality control in the ER, receptor
subpopulations are able to cycle toward the secretory pathways
of Golgi compartments and finally reach the cell surface. The
numbers of surface receptors, however, were insufficient to
enable functional ion channel formations (Schaefer et al., 2015).
Although, the X-ray structure of GlyRs has been recently solved
(Du et al., 2015; Huang et al., 2015), domain analysis will help to
understand the molecular processes of neurotransmitter binding,
translation of ligand-binding into channel opening and receptor
closure as well as to describe the pathomechanisms in affected
patients.
Here, we analyzed the recently discovered human mutations
G160R and T162M in loop B of the ECD and exchanged
the affected residues by other amino acids with respect to
differences in side chain volume and charge at amino acid
positions G160 and T162 close to the glycine-binding site. Our
aimwas to understand the importance of both residues within the
aromatic net shaping the conformation of the neurotransmitter-
binding site. We introduced at position G160 an alanine and a
serine present in other Cys-loop receptors at the corresponding
amino acid position. Both residues, G160 and T162, carry
small and uncharged side chains compared to the positively
charged arginine and the methionine carrying a hydrophobic
side chain identified in hyperekplexia patients. At position T162
we converted threonine into a negatively charged aspartic acid
(present in GABACpi and AChRα5), an asparagine able to form
hydrogen bond interactions with the peptide backbone (similar
to ELIC), and proline providing conformational rigidity (present
in GABAA γ2). The main focus of this study was on ligand-
efficacy and receptor trafficking. Whereas position 160 primarily
leads to decreased ligand potency, lowered agonist potency is
a secondary effect for mutations at amino acid position 162.
Changes at residue 162 located at the C-terminal end of loop
B result in ER accumulation with 50% or less receptor leaving
the ER toward the cell surface and the formation of functional
ion channels with highly disturbed agonist efficacies. Thus, the
appropriate sequence organization of loop B is a key component




All mutations were introduced by PCR using primers carrying
the appropriate mutation at the desired position (Invitrogen,
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Darmstadt, Germany). Amplimers carrying the mutations were
digested with restriction enzymes for cloning (Xho I and Hind
III). As parental clone GlyR α1 cDNA in the vector pRK5
was used. After digestion with Xho I and Hind III the PCR
products were subcloned into GlyR α1 wild type (wt). All
mutations were verified by sequencing (LGC Genomics, Berlin,
Germany).
Cell Lines
HEK293 cells (Human embryonic kidney cells) were
purchased from ATCC and grown in Earle’s minimal essential
medium (MEM) supplemented with 10% fetal calf serum,
200mM GlutaMAX, 100mM sodium pyruvate and 50U/mL
penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA)
under standard growth conditions at 37◦C and 5% CO2. COS7
cells (African green monkey kidney cells) were purchased
from ATCC and grown in Dulbecco’s modified Earle’s medium
(DMEM) with the same supplements added for HEK293 cells
and under the same growth conditions.
Transfection
HEK293 cells were transiently transfected using a modified
calcium-phosphate precipitation method, were a mixture of
plasmid DNA, CaCl2, and 2x HBS buffer (50mMHEPES, 12mM
glucose, 10mM KCl, 280mM NaCl, 1.5mM Na2HPO4) was
applied onto the cells.
COS7 cells were transfected with DNA diluted in PBS plus
10mg/mL DEAE-dextran (Sigma-Aldrich, St. Louis, MO, USA).
After 30min of incubation under standard conditions, media
was aspirated and fresh media containing 10mM chloroquine
was applied for 3 h. All experiments were done 24–48 h post-
transfection.
Biotinylation of Cell Surface Protein
The biotinylation assay was performed on HEK293 cells
transiently expressing the desired GlyR α1 (wt) or α1 variants.
Cells were plated on 10 cm dishes. 48 h after transfection,
medium was removed and cells were washed three times with
ice-cold PBS (GE Healthcare, Freiburg, Germany). The surface
proteins were labeled by incubating the cells for 30min with 1
mg/mL EZ-Link Sulfo-NHS-LC-biotin (sulfonosuccinimidyl-6-
(biotin-amido)-hexanoate (Pierce Biotechnologies, Rockford, IL,
USA), followed by incubation with quenching buffer (192mM
glycine, 25mM Tris in PBS, pH 8.0) for 10min. Cells were
detached by using ice-cold PBS buffer followed by centrifugation
for 10min at 1.000 g. Cell lysis was performed with TBS (Tris-
buffered saline) with 1% Triton-X100 and protease inhibitor
mixture tablet (Roche Diagnostics, Mannheim, Germany) and
centrifuged for 1min at 13.000 g. The supernatant (whole protein
fraction) was incubated with 50µl of streptavidin-agarose beads
(Pierce Biotechnologies, Rockford, IL, USA) for 2 h at 4◦C while
rotating. After removing the supernatant, beads were washed
three times in TBS buffer. Biotinylated proteins were eluted by
boiling with 50µl of 2x SDS buffer for 5min at 95◦C. 40µg of
surface proteins were analyzed by Western blot.
Protein Degradation Analysis on Whole
Cell Lysates
HEK293 cells transiently expressing GlyR α1 wt or α1
variants were incubated under standard growth conditions with
proteasome or lysosome inhibitors for specific time periods (all
inhibitors have been obtained from Sigma-Aldrich, St. Louis,
MO, USA). Cells were incubated with 1µM of MG132 for 1,
2, and 4 h. The lysosome inhibitor leupeptin (200µg/mL) was
incubated for 6, 12, and 24 h together with the transfected cells.
At each time point, media was aspirated and cells were washed
twice with PBS followed by incubation with CytoBuster Protein
Extraction Reagent (Merck Millipore, Darmstadt, Germany)
supplemented with protease inhibitor for 5min at room
temperature. The resulting cell suspension was centrifuged for
5min at 16.000 g and 4◦C resulting in a supernatant containing
solubilized proteins.
Western Blot Analysis—For SDS-PAGE, 11% polyacrylamide
gels were freshly prepared, followed by Western blot on
nitrocellulose membranes (GE Healthcare, Freiburg, Germany).
Membranes were blocked for 1 h with 5% BSA in TBS-T (TBS
with 1%Tween 20). Primary antibodies were incubated overnight
at 4◦C. GlyR α1 wt and GlyR mutants were detected with the
pan-α antibodyMAb4a (Synaptic Systems, Göttingen, Germany),
recognizing an epitope in the N-terminus of the GlyRs (residues
96–105). In biotinylation experiments, cadherin was chosen as
loading control detected by the pan-Cadherin antibody (Cell
Signaling Technology, Danvers, MA, USA). For lysate analysis,
GAPDH served as a loading control (Calbiochem, Darmstadt,
Germany). Signals were detected using the ECLplus system (GE
Healthcare, Freiburg, Germany).
Immunocytochemical Staining
Surface receptors were labeled following a co-transfection of
HEK293 cells with GlyR α1 (wt) or α1 variants together with
pDsRed-Monomer-Mem. pDsRed-Monomer-Mem (Clontech,
Mountain View, CA, USA) encodes a fusion protein consisting
of neuromodulin (GAP-43) and a red fluorescent protein
used as plasma membrane marker. For surface staining of
GlyR α1 in non-permeabilized cells, live cell staining was
performed using MAb2b for 1 h at 4◦C (1:500 in medium)
as primary antibody recognizing a native epitope (residue 1–
10 of mature protein at GlyR α1; Synaptic Systems, Göttingen
Germany). Intracellular GlyR α1 staining was done following
a co-transfection of HEK293 cells of α1 wt or α1 variants
and pDsRed-ER. pDsRed-ER (Clontech, Mountain View, CA,
USA) harbors the sequence information for a fusion protein
of calreticulin and red fluorescent protein and can therefore
be used as an ER marker. Cell staining was performed
following fixation with 4% paraformaldehyde and 4% sucrose
and a permabilisation/blocking step using PBS, 5% goat serum
and 0.1% Triton-X100. Here, the primary antibody MAb4a
(Synaptic Systems, Göttingen Germany) diluted 1:500 in PBS,
5% goat serum was used able to recognize the denatured
epitope. Cells were washed three times with PBS before the
secondary antibodies were applied for 30min. Here, goat anti-
mouse Alexa488 or goat anti-mouse Cy3 antibodies (Dianova,
Hamburg, Germany) were used 1:500 in PBS, 5% goat serum.
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 December 2015 | Volume 8 | Article 79
Atak et al. Loop B Residues and Glycine Potency
After a final wash, cells were embedded in Mowiol containing
DAPI (1:20.000) to mark the nucleus.
Compartmental Staining
COS7 cells transiently expressing GlyR α1 (wt) or GlyR α1
variants were stained in permeabilized cells with primary
antibodies MAb4a (Synaptic Systems, Göttingen Germany) and
a polyclonal anti-calnexin antibody (1:500, Abcam, Cambridge,
UK) for ER staining. The detection of ERGIC was done by
the monoclonal ERGIC53 antibody (1:500, Enzo Life Science,
Lörrach, Germany) and cis-Golgi stainings using a monoclonal
antibody anti-GM130 (1:500, BD Transduction Laboratories,
Heidelberg, Germany) together with a GlyR α1 specific antibody
(Chemicon, Darmstadt, Germany). Secondary antibodies used
were goat anti-mouse Cy3/Alexa488 and, goat anti–rabbit Cy3
(Dianova, Hamburg, Germany) diluted 1:500. All stainings
were subjected to confocal microscopy on a DMIRE2 confocal
microscope.
Electrophysiology
Maximal current amplifications (Imax) were measured by the
patch clamp technique in a whole-cell configuration mode.
Current signals were amplified with an EPC-9 amplifier
(HEKA, Lambrecht, Germany). 24 h after transfection, whole cell
recordings from HEK293 cells were performed by application
of ligand (glycine) in different concentrations using a U-tube
system. The extracellular buffer consisted of 137mM NaCl,
5.4mMKCl, 1.8mMCaCl2, 1mMMgCl2, 11mM EGTA, 10mM
HEPES, with a pH adjusted to 7.4 with NaOH. The internal
buffer was 120mM CsCl, 20mM N(Et)4Cl, 1mM CaCl2, 3mM
MgCl2, 11mM EGTA, 10mM HEPES with a pH adjusted to 7.4
with CsOH. Recording pipettes were fabricated from borosilicate
capillaries with an open resistance of about 4 M. Current
responses were measured at a holding potential of −60mV. All
experiments were carried out at room temperature. Error bars
refer to S.E.M. values.
Computational Methods
The homology model of the GlyR α1 was generated by using
the crystal structure of the glutamate-gated chloride channel
(GluCl) at 3.35 Å resolution (pdb code: 3RIF) as a template
(Hibbs and Gouaux, 2011). Both sequences were aligned
according to the ClustalW algorithm using the default settings
of the input form found at http://www.ch.embnet.org/software/
ClustalW.html (Thompson et al., 1994). The template structure
was modified by removing the Fab molecule bound to GluCl.
Molecular modeling was performed using MODELLER9.9
(Sánchez and Sali, 2000) with the ligand module. The disulfide
bridges were checked in the resulting model. The modeled
structure was improved by 200 steps of conjugated gradient
energy minimization using the Powell algorithm in Sybyl7.3 2002
St. Louis, MO, USA. The quality of the model was verified by
WHAT_CHECK (Hooft et al., 1996). Mutations were introduced
and positioned using Coot (Emsley et al., 2010). The visualization
of the structures was performed with the PyMOL Molecular
Graphics System, Version 1.7.6 (Schrödinger, LLC).
Statistical Analysis
Concentration-response curves were constructed from the peak
current amplitudes obtained with at least seven appropriately
spaced concentrations in the range 1–10.000µM glycine. Using a
non-linear algorithm (Microcal Origin), concentration-response
data were first analyzed using the following Hill equation
Iglycine/lsat = [glycine] nHill / [glycine]nHill+ EC
nHill
50 where Iglycine
refers to the current amplitude at a given glycine concentration,
Isat is the current amplitude at saturating concentrations of
glycine, EC50 is the glycine concentration producing half-
maximal current responses, and nHill is the Hill coefficient.
RESULTS
Localization of Loop B Mutants within the
GlyR
A homology model of the GlyR α1 was generated from the
GluCl crystal structure. The region between residues 157 and
162 is conserved within all GlyR subunits (Figure 1A). A
recently discovered patient suffering from hyperekplexia carries
a mutation at position G160 (pink) where glycine was mutated
to arginine (G160R). Another patient mutation is the conversion
of T162 (green) to methionine (T162M) again present in loop
B of the GlyR α1 ECD. Apart from these human mutations,
we generated constructs harboring other amino acids at both
positions G160 and T162 corresponding to residues in other Cys
loop receptors at the appropriate loop B position (Figures 1A,B).
G160A represents the change of a small hydrophobic side chain
compared to glycine whereas G160S harbors a hydrophilic side
chain. We also created T162A (small hydrophobic side chain),
T162D (negatively charged side chain), T162N (hydrophilic
side chain), and T162P (sterically demanding side chain). Both
residues G160 and T162 are localized in the center of the
neurotransmitter-binding site between adjacent subunits and
close to the aromatic residue F159, which was suggested to
directly interact with the incoming ligand glycine (Figure 1C).
Impact of Residues 160 and 162 in Loop B
on Receptor Expression
Live cell stainings for surface expression showed no obvious
differences between GlyR α1 wt and G160 variants (Figure 2A).
GAP-43 expressed as a fusion protein with dsRed encoded on a
co-transfected plasmid was used as membrane marker and for
control of transfection efficiency (Figures 2A,B, 3). The plasma
membrane detection of T162 variants at the single cell level
did not consider differences to wt (Figure 2C). Although, α1
labeled cells were rare for T162M and T162A (Figure 3). An
analysis of crude protein lysates (Figure 4A) was followed by
protein quantification from Western blots after pull-down of
biotinylated surface proteins by streptavidin binding. Protein
lysates provided first evidences for differences in expression levels
of α1 wt compared to α1 variants. The biotinylation method does
allow a direct comparison between whole cell protein expression
and surface protein expression. Here, significant differences of
surface protein levels were observed for T162 variants compared
to wt α1 (Figures 4B,C). The relative expression of the wt α1
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FIGURE 1 | Overview domain architecture of the GlyR. (A) The loop B region of amino acid residues 157–162 is highly conserved within the family of Cys-Loop
receptors. All glycine receptor subunits (α1–blue, α2, α3, β) carry the sequence of ESFGYT. A glycine is localized at position 160 (pink) and a threonine at position 162
(green). (B) Loop B mutations (gray letter) are shown and residues linked to hyperekplexia are marked by an asterisk (*). Glycine 160 was mutated into an alanine
G160A and a serine G160S. Threonine at position 162 was mutated into alanine, aspartate, asparagine and proline (T162A, D, N, and P). (C) Representation of two
GlyR α1 subunits of a receptor (blue and gray chain, respectively). For this homology model the crystal structure of GluCl (3RIF) was used as a template. Within the
loop B region of amino acid 157–162 (enlarged inlet) between β-sheets 7 and 8 of the ECD residues G160 (pink), T162 (green), and F159 (yellow) are marked.
was set to 1 (=100%). G160 variants were rather unaffected and
showed whole cell as well as surface levels comparable to wt.
T162M exhibited only marginal affected whole cell expression.
All other T162 receptors did not differ in the overall expression
levels (Figure 4C). T162M, T162D, T162P, and T162A revealed
reduced protein levels at the cellular surface. T162N was the
only mutant not affected in trafficking to the cell surface. The
mutation T162M identified in a patient with hyperekplexia and
T162D demonstrated significantly reduced surface expression
levels (T162M 29 ± 10%, T162D 40 ± 16%; Figure 4C).
Trafficking of T162P and T162A was decreased but did not
reach significance (T162P 64 ± 8%, T162A 82 ± 34%). A
determined portion of mutant GlyR protein seems to get stuck on
its way to the cell surface most probably in the ER compartment
as it has been shown previously for other recessive GlyR α1
mutants (Schaefer et al., 2015). The surface membrane fractions
were not contaminated with cytosolic proteins (Figure 4D).
Due to centrifugation of all cellular membranes followed by
solubilization of proteins out of membranes, all fractions
contained histone H3 usually forming tight associations with
scaffold proteins of the inner nuclearmembrane and are naturally
postranslationally biotinylated (Figure 4D; Polioudaki et al.,
2001; Bailey et al., 2008).
Effect of the Human Mutation T162M on
Protein Trafficking and Degradation
T162M colocalizes with calreticulin, a chaperone present in
the ER and important for protein quality control (Figure 5A).
It has been shown for the nicotinic acetylcholine receptor,
that calreticulin together with calnexin interact with newly
synthesized glycoproteins in the ER, stabilizing the receptors
and assisting in the folding process (Wanamaker and Green,
2007). Misfolded or unassembled protein is degraded via
the ER-associated degradation (ERAD) pathways, e.g., via the
proteasome. To determine ERAD of mutated GlyR α1, we
blocked the proteasomal degradation with the proteasome
inhibitor MG132 for different time periods (1, 2, and 4
h). We expected to observe protein accumulation since
misfolded receptor proteins would normally be degraded via
the proteasomal pathway. After a 1 h treatment with MG132,
protein distribution of GlyR α1 wt and T162M was similar in
the cytoplasm of transfected cells (Figures 5B,C). The protein
expression pattern of wt was rather stable up to 2 h of treatment
with only slight densities close to the nucleus at 4 h presence
of the blocking agent (Figure 5B). In contrast, accumulation of
T162M was already present after 2 h and even more prominent
after 4 h of treatment (Figure 5C). MG132 is a highly potent,
cell-permeable proteasome inhibitor. Since long incubation with
MG132 is toxic to cells, we quantified the GlyR α1 wt and T162M
protein amounts following proteasomal blocking following a
2 h presence of MG132 demonstrating a significant increase
of T162M protein compared to wt protein (Figures 6A,B).
Following 1 h incubation with MG132, the T162M starts to
accumulate, which is more prominent at 2 h MG132 treatment.
The lower degradation bands do also increase in intensity
between 1 and 2 h presence of the blocking agent (Figure 6A).
This might argue for less stable protein and higher turnover
rates of the mutated GlyRs. The GlyR α1 wt protein is not
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FIGURE 2 | Integration of GlyR variants into the cellular membrane. Different α1 mutants were expressed in HEK293 cells following co-transfection of a marker
for membrane expression (GAP-43 coupled to dsRed). (A) Overview images (first line) represent controls for transfection efficiency (GAP-43) for wt and G160 variants.
Below GlyR α1 homomers (green) expressed at cell surface (GAP-43 marker) are shown. G160R, G160A, and G160S mutants are well integrated into the cell surface.
(B) Transfection efficiency controls for cotransfections of T162 mutants together with GAP-43 coupled to dsRed. (C) Mutant GlyRs at position 162 (T162M, T162N,
T162D, T162P, and T162A) stained at the cell surface. All GlyR α1 were detected with the monoclonal MAb2b antibody. DAPI was used for staining of the nuclei.
affected at its protein level by a 2 h treatment with MG132.
It has been shown that ubiquitinated GlyRs expressed at the
cell surface are degraded by subsequent internalization and
lysosomal pathways (Büttner et al., 2001). To test if the mutant
T162M also uses this pathway for degradation, leupeptin was
utilized to block lysosomal degradation. Following treatment
with leupeptin, the T162Mmutation did not show any differences
upon leupeptin treatment after 6 h but reduced protein levels
after a 12 h treatment with leupeptin in contrast to GlyR α1 wt
(Figure 6A). The mutant T162M is still degraded in the presence
of leupeptin arguing for ongoing degradation using pathways
independent of degradation via lysosomes compared to α1 wt.
Subcompartmental analysis of GlyR α1 wt and T162M
was performed for the compartments ER, ERGIC and cis-
Golgi in Cos7 cells using co-stainings with marker proteins
present in these compartments. Cos-7 cells have been used
for subcompartmental analysis due to their large cytoplasm in
comparison to HEK293 cells. Calreticulin, a chaperone localized
at the ER exit sites for folded proteins, co-localized with the
T162M but only marginally with GlyR α1 wt (Figure 7A). The
GlyR α1 wt instead is observed at the outer most cytoplasm
and the membrane. T162M forms large accumulations in
the ER. ERGIC-53 is a protein of the ER-Golgi intermediate
compartment. Subpopulations of T162M pass the ERGIC and
cycle toward the cis-Golgi compartment where co-localisation
was observed with GM130 (Figures 7B,C). The GlyR α1 wt was
only present at some locations in ERGIC but no wt protein
was detectable in cis-Golgi, arguing for a fast forward trafficking
of the GlyR α1 wt receptors. The large ER accumulations of
mutated T162M protein in the ER might not only result from
the recognition of abnormally folded or incompletely assembled
T162M protein. Retrograde transport mechanisms from cis-
Golgi and ERGIC might also underlie this phenomenon.
Changes in Ligand Potencies of GlyR α1
Loop B Variants
The physiological characterization of the mutant receptor
populations was done by electrophysiological measurements
using whole-cell recordings following expression in HEK293
cells. In HEK293 cells, the EC50 of glycine for GlyR α1 wt
has been reported between 15 and 60µM. Therefore, we used
a glycine concentration of 100µM to determine whole-cell
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FIGURE 3 | Overview images demonstrating differences in GlyRα1 expression for T162 mutants. HEK293 cells were cotransfected with GlyR α1 wt (green)
or T162 variants together with the membrane marker GAP-43 coupled to dsRed (red). GAP-43 serves as a marker for transfection efficiency and colocalizes with GlyR
α1. Differences in GlyR expression of T162 variants in comparison to α1 wt were observed (first row).
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FIGURE 4 | Quantitative expression levels of mutant GlyRs. (A) Crude HEK293 whole cell lysates transiently expressing GlyR α1 (wt) or α1 variants. Loading
control GAPDH 37 kDa. (B) Biotinylation pull down experiments to quantify the protein expression of GlyR α1 variants and to distinguish between whole cell (WC) and
surface (SF) protein levels. The obtained data were taken from 4 independent experiments. The overall expression seems to be unaffected. Note, differences between
surface expression levels of wt and G160 compared to T162 variants. Pan-cadherin was used as a loading control. The GlyR α1 variants were stained at the
appropriate molecular weight of 48 kDa (black arrowheads), pan-cadherin appeared at 135 kDa (white arrowheads). (C) Quantification of protein levels determined
from whole cell (WC) and surface (SF) fractions from 4 independent experiments normalized to pan-cadherin (membrane marker protein). The expression levels are
shown in comparison to wild type (wt = 1). Error bars refer to standard error of the mean S.E.M. values. *p < 0.05, **p < 0.01 were considered significant. (D) Control
for purity of surface protein fraction. Surface (SF) and whole cell (WC) fractions were loaded from MOCK and wt α1 transfected HEK293 cells. Both fractions were
stained for the cytosolic protein GAPDH (37 kDa), the membrane marker pan-cadherin (135 kDa) and the nuclear marker histone H3 (17 kDa). Note, histones were
stained in all fractions due to (i) their localization attached to the inner nuclear membrane, (ii) naturally occurring posttranslational biotinylation of histones, and (iii)
binding to streptavidin beads following spin-down of membranes and solubilization of membrane attached proteins.
currents resulting in maximal currents for the wt expressing
cells. Irel currents of G160 mutants (white bars, Figure 8A)
were similar to wt. G160R evoked 69 ± 10% of the wt
current, G160A evoked 92 ± 12% of wt and G160S ended
up with 68 ± 22% of wt current. The reduction of the
observed inward currents for G160 mutant was, however, not
significant (Figure 8A, Table 1). T162 α1 variants (gray striped
bars, Figure 8A) showed significantly decreased inward currents
at 100µM glycine. T162M could only achieve 11 ± 5% of
I100µM compared to wt. T162N achieved 13 ± 3% and T162P
29 ± 10%. T162A was able to reach 4 ± 1% of maximum
current of wt (Figure 8A). Except T162D, all variants were able
to form functional receptors but evoked less inward currents. A
reduction of the inward current might be due to the observed low
expression of these mutated receptor complexes at the cellular
surface. The reduction of surface expression might not be the
major reason for inward current reduction as demonstrated
by T162N, which is indistinguishable from wt in cell surface
receptor numbers but resulted in a reduction of 85% of the wt
response. For T162D less than 1% of wt currents were measured
in two out of five cells recorded arguing for a non-functional
mutation.
Application of 100µM glycine did not result in obvious
changes for G160 variants. In addition, trafficking of G160
mutants is not affected. Determination of glycine potency
however showed significant differences. Using 7 different glycine
concentrations in a range of 1–1.000µM glycine, all G160
mutants showed reduced ligand potencies (EC50). GlyR α1
wt achieved its half maximal current at a concentration of
36 ± 10µM. The EC50 value determined for G160R was 92
± 13µM. A maximal concentration of glycine (1mM) was
not sufficient to reach saturation for GlyRα variants G160A
and G160S. However, both variants exhibit largely decreased
agonist potencies with EC50 values ≥ 383µM for G160A and
≥ 184µM for G160S (Figure 8B). The glycine concentration
to activate 50% of maximal currents (Imax) was increased by
a factor of 3–10 for G160 mutants. The effect was even more
prominent for T162M with more than a 21fold increase in
glycine EC50. The EC50 for the mutant T162M was 776± 96µM
(Figure 8B).
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FIGURE 5 | ER accumulation of T162M. (A) Following cotransfection into HEK293 cells, intracellular stainings of GlyR α1 T162M (MAb4a, green) and the ER
marker calreticulin expressed as a fusion protein coupled to dsRed (red). (B) Inhibition of the proteasomal pathway using MG132 for 1, 2, and 4 h. Following 2 h
presence of MG132, wt transfected cells (MAb4a, red signal) seemed rather unaffected in protein distribution. (C) In contrast, T162M (MAb4a, red) showed large
accumulations in the cellular lumen (white arrowheads, third lane, right picture). Lower lane represents pictures after 4 h treatment with MG132. Enlarged images are
shown in right column. GlyR wt (B) signal is dense, whereas T162M (C) is characterized by large protein aggregations localized close to the nucleus.
Conformational Changes by an
Introduction of a Negatively Charged
Residue in Loop B
Since the mutant T162D did not result in functional ion channels
although present to some extent at the cellular surface, we
followed T162D trafficking in transfected Cos7 cells (Figure 9A).
T162D passed the ERGIC and the cis-Golgi with no obvious
changes compared to T162M (Figure 7A). Similar to T162M,
ER accumulation was observed. The position T162 in the
GlyR seems to influence protein folding followed by ER export
(Figure 9A). When high saturating concentrations of glycine
(10mM) were applied to cells expressing T162D, the receptors
responded with maximal currents indistinguishable from GlyR
α1 wt (Figure 9B). Hence, the mutant T162D did not result in
non-functional ion channels rather physiological concentrations
of glycine are not sufficient to activate these GlyR channels.
Interestingly, the T162D channels close faster during ligand
washout compared to wt channels (Figure 9C). Homology
modeling of the T162D mutation revealed that the introduction
of a negatively charged aspartate likely allows a salt bridge
formation with the positively charged arginine R119 present
at the neighboring GlyR subunit in the pentameric receptor
complex (Figure 9D). Thus, a primary change, putatively in
the fold and flexibility of the ligand-binding site due to salt-
bridge formation, less ER export and integration in the outer
cellular membrane resulted secondary in an ion channel with an
unfavorable conformation of the ligand-binding pocket.
DISCUSSION
Glycinergic disinhibition results from either disrupting the
functionality of glycine receptors or trafficking disabilities.
So far, mutations in the gene GLRA1, the major common
cause for the neuromotor disorder hyperkplexia associated
with disturbances in glycinergic neurotransmission, have been
categorized into dominant mutations associated with functional
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FIGURE 6 | T162M degradation via the proteasomal degradation
pathway. (A) MG132 was added to transfected HEK293 cells expressing
either wt or T162M for 0, 1, and 2 h. Following incubation with the
proteasomal blocker, cell lysates (40µg per lane) were analyzed by Western
blotting (upper blot) using the GlyR antibody MAb4a (black arrowhead,
48 kDa). GAPDH 37 kDa served as a loading control (white arrowhead).
Inhibition of cellular lysosomes by leupeptin for 0, 6, and 12 h (lower blot),
GAPDH 37 kDa. GlyR protein is marked by black arrowhead. (B) Quantification
of protein levels after MG132 incubation for 1 and 2 h from 4 independent
experiments. T162M increased after 2 h proteasomal block, *p < 0.05.
disruptions and recessive mutants affecting receptor biogenesis
(Chung et al., 2010; Bode and Lynch, 2014). Recently, we could
demonstrate that disrupted trafficking does not necessarily result
in ER accumulation and degradation. Rather, subpopulations
of receptor are able to circumvent the ER quality control
and traffic through the secretory pathways of the Golgi
compartment. However only a minority is able to integrate
into the outer membrane. The receptor numbers at the
cell surface are insufficient to enable a normal glycinergic
function (Schaefer et al., 2015). Here, we analyzed in detail
human mutations localized within the GlyR ligand-binding sites
resulting from different modes of inheritance dominant—G160R
and recessive—T162M.
To get deeper insights into the importance of residues within
the ligand-binding site we mutated the affected residues into
amino acids present in other subtypes of the Cys-loop receptor
family—the closely related inhibitory receptors of the GABAA/C
family, the prokaryotic receptor ELIC and the C.elegans receptor
GluCl harboring the highest sequence identity to the glycine
receptor family among all Cys-loop receptor members (Hilf
and Dutzler, 2009; Hibbs and Gouaux, 2011). The mutant
G160R as well as the other two mutants G160A and G160S
showed no differences in expression levels compared to the wt
receptor α1. This was demonstrated by independent methods
of immunocytochemical as well as proteinbiochemical analyses.
Originally, G160R was identified in a patient with a dominant
mode of inheritance (Schaefer et al., 2015). G160 is localized
in direct neighborhood to F159, which has been shown to
be important for a cation-pi interaction with the incoming
ligand glycine (Schmieden et al., 1993; Pless et al., 2008). In a
recent study using a series of unnatural amino acids, a cation-
pi interaction between F159 and the amino groups of β-alanine
and taurine was also determined. Compared to the interaction
with glycine, the strength of interactions with taurine and β-
alanine was significantly weaker. This might be due to a different
orientation of the partial agonists within the ligand-binding
pocket (Pless et al., 2011). Similarly, mutations of other aromatic
residues contributing to the ligand-binding interface, e.g., F63,
F207 glycine concentrations of up to 300mM failed to saturate
the current responses (Grudzinska et al., 2005). Our analysis
of the ligand-binding potencies revealed a 3–10-fold decrease
in ligand-efficacy of glycine demonstrating the importance of
the small G160 to enable the correct conformation of the
ligand-binding pocket for the natural agonist. Interestingly, the
positively charged side chain of the arginine did not result
in a more drastically affected ligand potency compared to a
small side chain change e.g., in G160A. We conclude that the
smallest amino acid glycine harboring a hydrogen instead of a
side chain at position 160 of the human GlyR α1 is essential
to provide the optimal ligand-binding conformation for the
neurotransmitter glycine. Nevertheless, we cannot exclude other
factors such as differences in the transduction pathways following
ligand-binding enabling channel opening.
Residue T162 is also localized within the binding site. The
underlying mechanism of the human mutant T162M seems
to be a combination of affected biogenesis and functional
disruption. Only 50% of T162M receptors are able to reach the
cell surface obtained following transfection into heterologous
expression systems. Although, ER accumulation was observed,
the mutant was also detectable in compartments such as the
ER-Golgi intermediate compartment ERGIC as well as the cis-
Golgi. Therefore, the overall protein fold of T162M and T162D,
P, and A does not lead to a misfold resulting in lack of ER release
(Lippincott-Schwartz et al., 2000; Hebert and Molinari, 2007).
The subpopulations of T162 mutants reaching the cell surface
are, however, not sufficient to enable functionality of the GlyR
complex. We hypothesize retrograde signaling of mutated α1
subunits initialized by so far unknown control proteins within the
ERGIC and the cis-Golgi compartment resulting in proteasomal
degradation (ERAD degradation). Proteasomal degradation has
been shown for other recessive mutants (Villmann et al.,
2009). Moreover, a higher turnover of mutated α1 receptor
was exhibited by pulse-chase experiments. Here, we could
demonstrate that the mutated T162M resulted in cytoplasmic
accumulation after a 2 h treatment with the proteasomal
blocker MG132 in comparison to wt. For the wt receptor,
accumulation was first observed after a 4 h treatment but with
much less local protein close to the nuclear area compared to
T162M. Such accumulations in aggrosome-like structures close
to the nucleus have been demonstrated following proteasomal
blocking. Aggrosomes assemble to process misfolded proteins
that cannot well be handled by the ubiquitin-proteasome
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FIGURE 7 | Trafficking routes of T162M. (A) Costaining of T162M (MAb4a, red) and calreticulin (green), a chaperone and ER quality control protein in the ER in
transfected Cos7 cells. Note again large T162 accumulations in the ER compared to wt (upper lane, white dots marked by white arrowheads). (B) ERGIC co-staining
of GlyR wt and T162M (anti-α1, green) together with ERGIC-53 (pink). (C) Cis-Golgi staining using GM130 (pink) as a marker of the secretory Golgi compartment.
Mutant GlyR T162M (anti-α1, green) was visible in the cis-Golgi compartment. The white bar represents 30µm. Right column represents enlargements of merged
images (white dotted boxes).
pathway (Goldberg, 2003). Our calculation of T162M protein
following a block of proteasomal degradation resulted in a
significant increase of T162M protein levels after 2 h presence of
MG132.
Endocytosis followed by lysosomal degradation has been
shown for membrane-associated GlyR α1 wt (Büttner et al.,
2001). The incorporation of membrane proteins into endosomal
membranes is a common pathway formembrane-bound receptor
proteins. The GlyR α1 is a stable glycoprotein with a half-life
of approximately 2 days (Hoch et al., 1989). Following a 12 h
presence of the lysosomal blocker leupeptin, we indeed could
demonstrate accumulations of wt GlyR α1. Therefore, lysosomal
degradation does indeed represent the major degradation
pathway for the GlyR α1 wt protein.
In contrast, the T162M mutant was observed at much lower
receptor protein levels arguing for ongoing degradation in the
presence of leupeptin using pathways other than the lysosomal
pathway. However, we cannot exclude that the fraction of
T162M cell surface receptors might use lysosomal pathways
for degradation. The proportion of T162M receptors that does
not traffick to the cell surface is degraded via the proteasomal
pathway.
The fraction of T162 mutant receptor at the cell surface
diminishes glycinergic function to only 20% of wt activity
at a glycine concentration of 3-fold above EC50 for wt α1.
At glycine concentrations above physiological levels 3–10mM
the functionality of T162 mutants was indistinguishable from
wt receptors. Concentrations of up to 3.5mM glycine can be
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FIGURE 8 | Physiological changes in agonist potency due to affected loop B residues. Whole cell recordings on HEK293 cells transiently expressing GlyR α1
or mutant GlyR were performed to analyze receptor functionality and ligand potency. (A) Relative maximal currents (Imax) of G160 variants (left graph, white bars)
determined at 100µM glycine. Note, all T162 variants show reduced maximal currents (right graph, gray striped bars). n, number of independent measurements;
n = 7; *p < 0.05, **p < 0.01, ***p < 0.001. (B) EC50 measurements using glycine concentrations of 1, 3, 10, 30, 100, 300, 1000, 3000, and 10.000µM. GlyR α1
wt–black square, solid line; G160R–circles, dot-dashed line; G160A–triangle, dashed line; G160S–diamond, gray line; T162M–white circles, solid line. 1mM glycine
was used as a standard glycine concentration to determine I/Imax. n = 5–6.
TABLE 1 | Functional properties obtained from GlyR α1 mutants at positions 160 and 162.
Clone Number of Expression at Whole cell Number of Imax [pA] ± SEM Number of EC50 gly [µM] ± SEM
independent experiments cell surface expression cells cells
GlyR α1 wt 4 +++ +++ 7 1571 ± 260 5 36 ± 10
UT 4 - - - - - -
MOCK 4 - - - - - -
α1 G160R 4 ++ +++ 7 1089 ± 167 5 92 ± 13
α1 G160A 4 ++ +++ 8 1453 ± 197 6 ≥ 383
α1 G160S 4 ++ +++ 8 1061 ± 359 5 ≥ 184
GlyR α1 wt 4 +++ +++ 17 2916 ± 371 5 36 ± 10
α1 T162M 4 + ++ 10 309 ± 154*** 6 776 ± 96
α1 T162A 4 ++ +++ 5 148 ± 45** - n.d.
α1 T162D 4 + +++ 7 10 ± 6*** - n.d.
α1 T162N 4 +++ +++ 5 447 ± 96** - n.d.
α1 T162P 4 ++ +++ 5 832 ± 300* - n.d.
*UT refers to untransfected cells and MOCK to GFP transfected cells used as controls. n, number of independent experiments; SEM (standard error of the mean), n.d. not determined,
p-values refer to the appropriate WT *p < 0.05, **p < 0.01, ***p<0.001.
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FIGURE 9 | Subcompartmental distribution of T162D. (A) Transfected Cos7 cells were used to co-stain GlyR α1 T162D (pink) with calreticulin (green). Large ER
accumulations (white dots marked by white arrow heads) were obvious (right picture, first lane). Costaining of T162D (anti-α1, green) with ERGIC (pink, second lane),
colocalization with GM130 (pink, third lane). Right pictures demonstrate enlarged areas of the white dotted box in the merged picture. (B) Whole cell maximal currents
of T162D compared to α1 wt at saturating concentrations of glycine (10mM). (C) Single traces of 10mM recordings from wt and T162D. Note, the fast channel
closure compared to wt channels during washout of very high glycine concentrations. (D) View from the side onto the ligand-binding site at the interface of two
adjacent GlyR subunits (blue and gray), with bound glycine (in ball-and-stick representation). Residue D162 is marked in green, F159 in beige, further aromatic
residues lining the glycine binding site (Y202, F63) are beige and R119 shown in red with putative salt bridge indicated by black dashed lines and distances given in Å.
Note, F63 and R119 are localized at the neighboring subunit.
reached during activation (Beato, 2008), however, the fraction
of cell surface receptors might still be too low to enable
inhibitory neurotransmission in the human organism. The EC50
for T162M shows a 21-fold increase indicating a disruption of
the ligand-binding site. The artificial mutant T162D resulted
in non-functional channels following glycine application of
concentrations 3-fold above EC50 for wt α1. At very high
concentrations of glycine, mutated T162D receptors were able to
open. A conformational change required to open the ion channel
pore seems therefore not be hindered by the mutation rather
high glycine concentrations are necessary to allow activation of
channels.
Modeling of the mutant T162D demonstrated that the
mutation of T162 into an aspartate might result in novel
interactions with other residues from the neighboring subunit.
The introduction of the negatively charged aspartate would
enable the formation of a salt bridge together with R119 from
the neighboring subunit. One might speculate that the novel salt
bridge stabilizes the protein conformation and does not result
in misfolding allowing receptor forward trafficking from the ER
to further cell compartments. Following integration into the cell
surface the receptor configuration is less favorable to get activated
by the neurotransmitter glycine. In vivo, such GlyR α1 mutants
may provide cell stress to motoneurons resulting in a more severe
phenotype of these patients compared to patients carrying a
NULL-allele (Brune et al., 1996; Becker et al., 2006) suffering
from a rather mild form of hyperekplexia.
In summary, residues G160 and T162 localized in loop
B of the GlyR α1 protein lining the ligand-binding pocket
are essential determinants for ligand potency. Both residues
when mutated lead to significant decreases in ligand potency.
In contrast to G160, where the functional disturbances are a
primary consequence of the mutation, the observed functional
impairment of T162 mutants is most probably a secondary
effect. Primarily, lack of threonine 162 leads to changes in the
overall protein biogenesis, but mutant receptors are still sufficient
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 December 2015 | Volume 8 | Article 79
Atak et al. Loop B Residues and Glycine Potency
to circumvent the ER quality control. The small fraction of
cell surface receptors is not able to sustain normal glycinergic
neurotransmission. Hence, loop B residues are crucial elements
within the conformation of the ligand-binding pocket.
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